Document:

Exhibit
10.22

 

EXECUTIVE
EMPLOYMENT AGREEMENT

 

This
Executive Employment Agreement (the “Agreement”) is made effective on the Effective Date set forth below between Vitro
Diagnostics, Inc., a Nevada Corporation (the “Company”) and Keith V. Burge (‘‘Executive’’).

 

WITNESETH:

 

WHEREAS,
the Company wishes to engage the services of Executive in the position of Chief Operating Officer on the terms and conditions set
forth below; and

 

WHEREAS,
Executive and Company wish to enter into this Agreement regarding the terms of Executive’s employment which shall become effective
upon the date of last execution of this Agreement (the ·’Effective Date”).

 

NOW,
THEREFORE, in consideration of the premises and mutual promises set forth herein, the sufficiency of which is hereby acknowledged,
the parties agree as follows:

 

I.
Engagement: Duties. The Company hereby engages the Executive effective as of the Effective Date as its Chief Operating Officer.
Executive’s principal area of responsibility, subject to modification by the Company, shall be to serve as the Chief operating
Officer with all the duties and responsibilities customarily associated with this position. Executive will report to and shall be under
the supervision of the Chief Executive Officer (the “CEO’’). His job duties will include overseeing all the
operations of the company in support of the CEO that do not have a direct report to the CEO. The executive will promote the business
development of the company, sales and marketing, social media marketing. oversee and interact with the company’s business partnerships,
business agreements and arrangements, interact on a peer level with other members of the executive management team while reporting directly
to and supporting the objectives of the CEO.

 

2.
Board Membership. The executive will not be on the company’s board at this time.

 

3.
Best Efforts. Executive agrees to use his best efforts to promote the interests of the Company and shall, except for illness,
reasonable vacation periods and leaves of absence, devote four days of a business week (‘‘Part Time Schedule’’)
of his time and energies to the business and affairs of the Company. Executive may perform his duties under this Agreement from any
location approved by the Board, including the Company’s office. Executive shall be permitted to continue to manage and participate
in his outside businesses that are not competitive with Company provided that those activities do not interfere with his activities on
behalf of the Company. Executive, in his discretion, may increase his services to the Company from a Part-Time Schedule to five (5) days
per week (‘‘Full Time Schedule’’) in the future.

 

4.
Term of Agreement. The term of this Agreement shall commence on the Effective Date and shall continue, unless earlier terminated
in accordance with the terms of Section 6 of this

 

    	Page I of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

Agreement,
for a period of five years (the ‘‘Initial Term”). The Initial Term shall be extended automatically for an additional
one-year periods (each, a ‘‘Renewal Term”) unless either party gives notice to the other that this Agreement
will not be extended at least ninety (90) days prior to the expiration of the Original Term or any Renewal Term (a “Non-Renewal
Notice”). This Agreement shall commence on the Effective Date and continue until termination by non-renewal by either party
or in accordance with Section 6 (the “Term’”).

 

5.
Compensation and Benefits.

 

		5.1	Base
                                            Salary.

 

 5.1.1 For the Initial Term, Executive’s Base Salary shall be $175,000 per annum. Payable bi-monthly.

 

		5.2	Bonuses
                                            and Stock Options

 

5.2.1
Annual Bonus. In addition to the Base Salary described in section 4.1 (above), Executive shall be entitled to receive an annual
bonus of up to 50% of the base salary as determined by the CEO.

 

		(a)	Stretch
                                            Bonus. Executive shall also be entitled to receive a stretch bonus (‘‘Stretch
                                            Bonus’’) as determined by the CEO and the Board of Directors on account of
                                            extraordinary success in furthering the company’s business objectives.

 

5.2.2
Stock Options. Stock options shall be granted to the Executive upon execution of this Agreement exercisable to purchase up to
One Million (1,000,000) shares of the Company’s common stock at an exercise price of $0.50 cents per share (the “Options”).
The Options will be Non-Qualified Stock Options. Except as otherwise provided in this Agreement, the Options will vest at the rate
of One Million (200,000) options per year for five (5) years subject to Executive’s continuing service to the Company. The Options
will have a cashless exercise provision. These Options shall be exercisable for a period of ten (10) years from the date of grant beginning
with the date of vesting. The Company also agrees that all Options as provided herein shall immediately vest in the Executive upon a
Change in Control of the Company as defined below. The Options grant shall be governed by the applicable award agreement, which shall
be in substantially the same form as Exhibit B including without limitation the vesting and exercisability provisions set forth therein.

 

5.2.3
Benefits. . Executive shall be entitled to participate in all benefit programs established by the Company and generally applicable to
the Company’s executive employees. Employee shall also be reimbursed for reasonable and necessary business expenses incurred in
the course of his employment with the Company pursuant to Company policies as established from time to time.

 

    	Page 2 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

6.
Termination of Employment Relationship.

 

6.1
Death or Disability. This Agreement shall terminate immediately upon the death or Disability of Executive, and in such event,
the Executive shall have no further claim against the Company for compensation or benefits hereunder except as provided herein. ‘‘Disability”
means a physical or mental incapacity of Executive that has prevented the Executive from performing the duties customarily assigned
to the Executive for one hundred and eighty (180) calendar days, whether or not consecutive, out of any twelve (12) consecutive months
and that in the opinion of the Board or any committee thereof, acting on the basis of a written opinion from a duly qualified medical
practitioner, is likely to continue to a similar degree. Upon request, such written opinion shall be provided to Executive or his authorized
representative(s) no later than ten (10) days from the date requested.

 

6.2
Termination by the Company for “Cause”. This Agreement may be terminated by the Company for “Cause” and,
in such event, this Agreement and Executive’s employment with the Company shall terminate on the termination date designated by
the Company. Provided, however, prior to the effective date of termination, the Company shall provide written notice to Executive describing
in reasonable detail the for ‘‘Cause” reason for termination and provide Executive an opportunity to appear before
the Board (with or without counsel) to discuss the circumstances constituting the “Cause’’. For the purpose of this
paragraph, ‘‘Termination for Cause” or ‘‘Cause” shall include the following:

 

6.2.1
Willful misconduct or gross negligence in the performance of any of Executive’s duties to the Company, which creates a demonstrative
material and adverse effect on the business, reputation or financial condition of the Company, and if capable of being cured, is not
cured to the reasonable satisfaction of the Board within thirty (30) days after Executive receives from the Board written notice of such
willful misconduct or gross negligence;

 

6.2.2
The commission of any crime (whether or not a felony) involving fraud, theft, breach of trust or similar acts, whether of the United
States or any state thereof to which the Executive may be subject; or

 

6.2.3
Any material breach of Section 7 of this Agreement, and if capable of being cured, is not cured to the reasonable satisfaction of the
Board within thirty (30) days after Executive receives from the Board written notice of such breach.

 

6.3
Resignation by Executive Without Good Reason. Executive may terminate this Agreement and the Executive’s employment with
the Company at any time and without Good Reason (defined below) by providing the Company with at least one month of notice in writing
or by electing not to renew the Term after the expiration of the Initial Term or any subsequent Renewal Term, as applicable. If, upon
receipt of the Executive’s resignation or Non-Renewal Notice (or any later date during such notice period), the Company terminates
the Executive’s employment before the date the resignation was to be effective, the Company shall, in full satisfaction of its
obligations to the Executive: (a) pay the Executive’s Base Salary and vacation pay accrued until the date the resignation was to
be effective up to a maximum of three months; and (b) reimburse the outstanding expenses properly incurred by the Executive until the
date the Executive’s employment ceases and submitted for reimbursement.

 

    	Page 3 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

6.4
Termination by the Company without Cause or Resignation by Executive for Good Reason. The Company may terminate the Executive’s
employment at any time without Cause, on providing thirty (30) days’ written notice to the Executive, or by electing not to renew
the Term after the expiration of the Initial Term or any subsequent Renewal Term, as applicable. Executive may elect not to renew the
Term after the expiration of the Initial Term or any subsequent Renewal Term for “Good Reason” or terminate this Agreement
at any time for ·’Good Reason”. For purposes of this paragraph, Good Reason shall mean:

 

6.4.1
Any removal of the Executive from or failure to re-elect the Executive as Chief Operating Officer without his consent, except in connection
with termination of the Executive pursuant to Section 6.1 or 6.2 hereof;

 

6.4.2
A reduction in the Executive’s compensation, or any other material failure of the Company to comply with Section 5 (Compensation)
hereof;

     

 6.4.3 The assignment to the Executive of duties materially different than the duties assigned to the Executive hereunder or a material diminution in the Executive’s title, status, seniority, reporting relationship, responsibilities or authority;

 

6.4.4
Any change in the situs of the Company’s principal offices and facility of requiring the Executive to travel more than 50 miles
each way more than two times per week;

 

 6.4.5 Other material breach of this Agreement by the Company; or

 

6.4.6
Change in Control of the Company. As used herein, a “Change in Control” means the occurrence of any of the following after
the Effective Date:

 

		(a)	any
                                            merger or consolidation of the Company with or into another entity (other than any such merger
                                            or consolidation in which the shareholders of the Company immediately prior to such merger
                                            or consolidation continue to hold at least a majority of the voting power of the outstanding
                                            capital stock or other ownership interests in the surviving corporation);

 

		(b)	any
                                            sale, transfer, or other disposition, in a single transaction or series of related transactions,
                                            of all or substantially all of the assets of the Company;

 

    	Page 4 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

		(c)	any
                                            other transaction or series of related transactions pursuant to which a single person or
                                            entity (or group of affiliated persons or entities) acquires from the Company or its shareholders
                                            a majority of the voting power of the outstanding capital stock or other ownership interest
                                            in the Company; or

 

		(d)	a
                                            majority of the members of the Board are replaced during any twelve-month period by directors
                                            whose appointment or election is not endorsed by seventy-five percent (75%) of the Board
                                            before the date of appointment or election.

 

6.5
Payment Upon Termination under Sections 6.1 6.2 and 6.3.

 

 6.5.1 If this Agreement is terminated by the Company for Cause pursuant to Section 6.2 or in the event of Executive’s death or Disability as set forth in Section 6.1 or Executive resigns without Good Reason or does not renew this Agreement upon expiration of the Initial Term or a Renewal Term, as applicable, pursuant to Section 6.3, Company shall (i) pay the Executive’s Base Salary and vacation pay accrued, if applicable, until the date the Executive’s employment terminates; and (ii) reimburse the outstanding expenses properly incurred by the Executive until the date the Executive’s employment terminates and submitted for reimbursement. In such circumstances, Executive shall be ineligible for any Annual Bonus for the year of termination, and any entitlements in respect of equity-based awards shall be governed by the terms and conditions of the applicable equity award plan, any other applicable plan and the applicable award agreement; provided, however, that in the event of death or Disability, Executive shall be entitled to a bonus payment calculated in accordance with Section 6.6.1(iii) below.

 

6.6
Payment Upon Termination under Section 6.4. In the event that Executive resigns with Good Reason or the Company terminates Executive’s
employment without Cause or by electing not to renew this Agreement, the Company shall (i) pay two times the Executive’s Base annual
Salary and vacation pay accrued, if applicable and (ii) reimburse the outstanding expenses properly incurred by the Executive until the
date the Executive’s employment terminates and submitted for reimbursement; (iii) pay Executive an amount equal to two times the
average of Executive’s Annual Bonuses (as contemplated by Section 5.2.2 herein) for the two years immediately preceding Executive’s
termination under this subsection 6.6.I, payable in a lump sum no later than thirty (30) days from the date of termination (iv) pay Executive
the Stretch Bonus as determined by the CEO . In addition, all Options granted to Executive shall be deemed fully vested and exercisable
for the remaining term of such Options.

 

6.7
280G.

 

6.7.1
Notwithstanding any other provision of this Agreement or any other plan, arrangement or agreement to the contrary, if any of the payments
or benefits provided or to be provided by the Company to the Executive or for the Executive’s benefit pursuant to the terms of
this Agreement or otherwise (“Covered Payments”) constitute parachute payments (“Parachute Payments”)
within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and will be subject
to the excise tax imposed under Section 4999 of the Code (or any successor provision thereto) or any interest or penalties with respect
to such excise tax (collectively, the “Excise Tax”), then the Company shall pay to the Executive, no later than the
time the Excise Tax is required to be paid by the Executive or withheld by the Company, an additional amount (the “Gross-up
Payment”) equal to the sum of the Excise Tax payable by the Executive, plus the amount necessary to put the Executive in the
same after-tax position (taking into account any and all applicable federal, state, local and foreign income, employment and excise taxes
(including the Excise Tax and any income and employment taxes imposed on the Gross-up Payment)) that he would have been in if the Executive
had not incurred any tax liability under Section 4999 of the Code.

 

    	Page 5 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

6.7.2
Any determination required under this Section 6.7 shall be made in writing in good faith by the accounting firm which was the Company’s
independent auditor immediately before the Change in Control (the “Accountants”), which shall provide detailed supporting
calculations to the Company and the Executive as requested by the Company or the Executive. Company and the Executive shall provide the
Accountants with such information and documents as the Accountants may reasonably request in order to make a determination under this
Section 6.7. For purposes of making the calculations and determinations required by this Section 6.7, the Accountants may rely on reasonable,
good faith assumptions and approximations concerning the application of Section 280G and Section 4999 of the Code. The Accountants’
determinations shall be final and binding on the Company and the Executive. The Company shall be responsible for all fees and expenses
incurred by the Accountants in connection with the calculations required by this Section 6.7.

     

6.7.3
In light of the uncertainty in applying Section 4999 of the Code, if it is subsequently determined that the Gross-up Payment is not sufficient
to put the Executive in the same after-tax position (taking into account any and all applicable federal, state, local and foreign income,
employment and excise taxes (including the Excise Tax and such taxes imposed on the Gross-up Payment)) that he would have been in if
the Executive had not incurred the Excise Tax, then the Company shall promptly pay to or for the benefit of the Executive such additional
amounts necessary to put the Executive in the same after-tax position that he would have been in if the Excise Tax had not been imposed.
In the event that a written ruling of the Internal Revenue Service (IRS) is obtained by or on behalf of the Company or the Executive,
which provides that the Executive is not required to pay, or is entitled to a refund with respect to, all or a portion of the Excise
Tax, then the Executive shall reimburse the Company in an amount equal to the Gross-up Payment, less any amounts which remain payable
by or are not refunded to the Executive, within thirty (30) days of the date of the IRS determination or the date the Executive receives
the refund, as applicable. Executive and Company shall reasonably cooperate with each other in connection with any administrative or
judicial proceedings concerning the existence or amount of liability for the Excise Tax.

 

    	Page 6 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

6.8
Survival. The provisions of this Section 6 shall survive the termination of this Agreement and the termination of Executive’s employment.

 

7.
Non-Competition Agreement.

 

7.1
Competition; Confidential Information. The Executive and the Company recognize that due to the nature of his engagements hereunder,
and the relationship of the Executive to the Company, the Executive has had access to and has acquired, will have access to and will
acquire, and has assisted in and may assist in developing, confidential and proprietary information relating to the business and operations
of the Company and its affiliates, including, without limiting the generality of the foregoing, information with respect to their present
and prospective products, systems, customers, agents, processes, and sales and marketing methods. The Executive acknowledges that such
information has been and will continue to be of central importance to the business of the Company and its affiliates and that disclosure
of it to or its use by others could cause substantial loss to the Company. The Executive and the Company also recognize that an important
part of the Executive’s duties will be to develop goodwill for the Company and its affiliates through his personal contact with
customers, agents and others having business relationships with the Company and its affiliates, and that there is a danger that this
good will, a proprietary asset of the Company and its affiliates, may follow the Executive if and when his relationship with the Company
is terminated. Executive acknowledges that his services to be rendered hereunder have a unique value to the Company, for the loss of
which the Company cannot be adequately compensated by damages in an action at law.

 

7.2
Non-Competition. In view of the unique value to the Company of the services of Executive, and because of the Confidential Information
to be obtained by or disclosed to Executive, and as a material inducement to the Company to enter into this Employment Agreement and
to pay to Executive the compensation referred to in Paragraph 4 hereof, Executive covenants and agrees that:

 

7.2.1
While Executive is employed by the Company and for a period of one year thereafter (the “Non-Competition Period’’),
Executive will not, either personally, as an officer, director, owner, manager, member, principal, partner, executive, agent, distributor,
representative, stockholder, consultant or otherwise, or with or through any other person or entity operate or participate in any business
which is directly competitive with the Company nor will Executive, during the Non-Competition Period and for a period of one (I) year
thereafter, directly or indirectly solicit any person who has been a customer of the Company during the period of one (1) year prior
to the termination of employment. This non-competition clause shall apply in the geographic territory comprised of the entire United
States and any other geographic area in which the Company is actively engaged in business on the date Executive’s employment terminates.
Executive acknowledges that Executive has special knowledge of the business of the Company and that this non-competition/non- solicitation
agreement is reasonable in terms of its scope and duration.

 

    	Page 7 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

7.2.2
Nothing in this Section 6.2 shall be construed to prevent the Executive from owning, as an investment, not more than five percent (5%)
of a class of equity securities issued by any competitor of the Company or its affiliates and publicly traded and registered under Section
12 of the Securities Exchange Act of 1934.

 

7.3
Trade Secrets. The Executive will keep confidential any trade secrets or confidential or proprietary information of the Company
and its affiliates which are now known to him or which hereafter may become known to him as a result of his employment or association
with the Company and shall not at any time directly or indirectly disclose any such information to any person, firm or corporation, or
use the same in any way other than in connection with the business of the Company or its affiliates during and at all times after the
expiration of or termination of this Agreement. For purposes of this Agreement, “trade secrets or confidential or proprietary information”
means information unique to the Company or any of its affiliates which has a significant business purpose and is not known or generally
available from sources outside the Company or any of its affiliates or typical of industry practice. Trade secrets or confidential or
proprietary information may include information with respect to the Company’s personnel records, present and prospective products,
systems, customers, agents, processes, and sales and marketing methods.

 

7.4
Patents. The Executive will assign to the Company exclusive rights to any patents awarded to him on the basis of ideas developed
and reduced to practice by the Executive for the Company or its affiliates during the Term of Employment that are developed as part of
Executive’s services under this Agreement.

 

7.5
Injunctive Relief. It is agreed that Executive’s services are unique, and that any breach or threatened breach by Executive
of any provisions of this Section 7 may not be remedied solely by damages. Accordingly, in the event of a breach or threatened breach
by Executive of any of the provisions of this Section 7, the Company shall be entitled to injunctive relief, restraining Executive from
engaging in any activity which would constitute a breach of this Section 7. Nothing herein, however, shall be construed as prohibiting
the Company from pursuing any other remedies available at law or in equity for such breach or threatened breach, including the recovery
of damages.

 

7.6
Survival. The provisions of this Section 7 shall survive the termination of this Agreement and the termination of Executive’s
employment.

 

8.
Section 409A.

 

8.1.
This Agreement is intended to comply with Section 409A of the Code, as amended (“Section 409A”) and shall be construed
accordingly. It is the intention of the Parties that payments or benefits payable under this Agreement not be subject to the additional
tax or interest imposed pursuant to Section 409A. To the extent such potential payments or benefits are or could become subject to Section
409A, the Parties shall cooperate to amend this Agreement with the goal of giving Executive the economic benefits described herein in
a manner that does not result in such tax or interest being imposed; provided, however, that no such amendment shall materially increase
the cost to, or impose any liability on Company with respect to any benefits contemplated or provided hereunder. Executive shall, at
the request of Company, take any reasonable action (or refrain from taking any action), required to comply with any correction procedure
promulgated pursuant to Section 409A.

 

    	Page 8 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

8.2.
If a payment that could be made under this Agreement would be subject to additional taxes and interest under Section 409A, Company in
its sole discretion may accelerate some or all of a payment otherwise payable under the Agreement to the time at which such amount is
includible in the income of Executive, provided that such acceleration shall only be permitted to the extent permitted under Treasury
Regulation§ l .409A-3 (j)(4)(vii) and the amount of such acceleration does not exceed the amount permitted under Treasury Regulation§
l .409A-3 (j)(4)(vii)

 

8.3.
No payment to be made under this Agreement shall be made at a time earlier than that provided for in this Agreement unless such payment
is (i) an acceleration of payment permitted to be made under Treasury Regulation§ 1.409A-3 (j)(4) or (ii) a payment that would otherwise
not be subject to additional taxes and interest under Section 409A.

 

8.4.
The right to each payment described in this Agreement shall be treated as a right to a series of separate payments and a separately identifiable
payment for purposes of Section 409A.

 

8.5.
For purposes of Section 6 of this Agreement, “termination” (or any similar term) when used in reference to Executive’s
employment shall mean “separation from service” with Company within the meaning of Section 409A(a)(2)(A)(i) of the Code and
applicable administrative guidance issued thereunder, and Executive shall be considered to have terminated employment with Company when,
and only when, Executive incurs a “separation from service” with Company within the meaning of Section 409A(a)(2)(A)(i) of
the Code and applicable administrative guidance issued

thereunder.

 

8.6.
If Executive qualifies as a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code and would receive
any payment sooner than six (6) months after Executive’s separation from service that, absent the application of this Section I8(t),
would be subject to additional tax imposed pursuant to Section 409A as a result of such status as a specified employee, then such payment
shall instead be payable on the date that is the earliest of (i) six (6) months after Executive’s separation from service, (ii)
Executive’s death, or (iii) such other date as will not result in such payment being subject to such additional tax.

 

8.7.
A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment
of any amounts or benefits upon or following a termination of employment unless such termination is also a “separation from service”
within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,”
“termination of employment” or like terms shall mean “separation from service.”

 

    	Page 9 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

9.
Indemnification. The Company shall indemnify the Executive to the maximum extent that its officers, directors and employees are
entitled to indemnification pursuant to the Company’s certificate of incorporation, bylaws, and any indemnification agreements
then in force, subject to applicable law. The Executive shall also be covered as an insured under any contract of directors and officers
liability insurance to the same extent as such contract covers members of the Board. The Executive’s rights under this Section
9 shall survive any termination or expiration of this Agreement and any termination of the Executive’s employment for all periods
thereafter during which the Executive may be subject to liability for any acts or omissions occurring during his employment or service
as a member of the Board that is otherwise subject to indemnification and coverage under directors and officers liability insurance.

 

10.
Miscellaneous.

 

10.1.
Assignability. Executive may not assign his rights and obligations under this Agreement without the prior written consent of the
Company, which consent may be withheld for any reason or for no reason. This Agreement and all of its rights, privileges, and obligations
will be binding upon the parties and all successors and agreed to assigns thereof.

 

10.2.
Severability. In the event that any of the provisions of this Agreement shall be held to be invalid or unenforceable, the remaining
provisions shall nevertheless continue to be valid and enforceable as though the invalid or unenforceable parts had not been included
therein. Without limiting the generality of the foregoing, in the event that any provision of Paragraph 6 relating to time period and/or
areas of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period or areas(s) such court
deems enforceable, said time period and/or area(s) of

restriction
shall be deemed to become, and thereafter be, the maximum time period and/or area for which such are enforceable.

 

10.3.
Entire Agreement. This Agreement constitutes the entire agreement between the parties relating to Executive’s employment
as Chief Operating Officer of the Company, and supersedes all prior agreements or understandings among the parties hereto with respect
to Executive’s employment as Chief Operating Officer of the Company.

 

10.4.
Amendments. This Agreement shall not be amended or modified except by a writing signed by both parties hereto.

 

10.5.
Waiver. The failure of either party at any time to require performance of the other party of any provision of this Agreement shall
in no way affect the right of such party thereafter to enforce the same provision, nor shall the waiver by either party of any breach
of any provision hereof be taken or held to be a waiver of any other or subsequent breach, or as a waiver of the provision itself.

 

    	Page 10 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

10.6.
Choice of Law. This Agreement shall be governed by and interpreted in accordance with the laws of the State of Colorado without
regard to the conflict of laws of such State.

 

10.7.
Binding Agreement. This Agreement shall be effective as of the date hereof and shall be binding upon and inure to the benefit
of the Executive, his heirs, personal and legal representatives, guardians and permitted assigns. The rights and obligations
of the Company under this Agreement shall inure to the benefit of and shall be binding upon any successor or assignee of
the Company.

 

10.8.
Headings. The headings or titles in this Agreement are for the purpose of reference only and shall not in any way affect the interpretation
or construction of this Agreement.

 

10.9.
Legal Fees. Within thirty (30) days of the Effective Date, the Company agrees to pay the legal expenses of Executive in the negotiation
and preparation of this Agreement and its exhibits, not to exceed $7,500.

 

10.10.
Arbitration. Any dispute between the Company and the Executive with respect to this Agreement shall be submitted to binding
arbitration in Jefferson County, Colorado pursuant to the rules of the American Arbitration Association then in
effect and before an arbitrator fully licensed and authorized by any and all applicable rules, statutes, regulations or the like
to hear such cases in the State of Colorado. The arbitrators shall have the power to award any legal or equitable remedies that would
be available in proceedings conducted before a state or federal court of competent jurisdiction in Colorado. The arbitrators shall have
the power to award to the substantially prevailing party in any arbitration such party’s reasonable attorneys’ fees and costs
incurred in such arbitration against the losing party as set forth in Section 7.14 of this Agreement. Judgment on the award of the arbitrators
may be entered in any court of competent jurisdiction. All arbitration proceedings and the results thereof shall be confidential,
except to the extent that any party is required to make disclosure concerning such proceedings under applicable law.

 

10.11.
No Conflict. The Executive represents and warrants that he is not subject to any agreement, order, judgment or decree of any kind
which would prevent him from entering into this Agreement or performing fully his obligations hereunder.

 

10.12.
Survival. The rights and obligations of the parties shall survive the Term of Employment to the extent that any performance is
required under this Agreement after the expiration or termination of such Term of Employment.

 

10.13.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of
which shall together constitute one and the same document.

 

10.14.
Notices. Any notice to be given hereunder by either party to the other may be affected in writing by personal delivery, or by
mail, certified with postage prepaid, or by overnight delivery service. Notices sent by mail or by an overnight delivery service shall
be addressed to the parties at the addresses appearing following their signatures below, or upon the employment records of the Company
but either party may change its or his address by written notice in accordance with this paragraph.

 

    	Page 11 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

10.15.
Opportunity to Consult Counsel. The Parties hereto represent and agree that, prior to executing this Agreement, each has had the
opportunity to consult with independent counsel concerning the terms of this Agreement.

 

10.16.
Attorney Fees. In the event of any dispute, arbitration, litigation between the Parties or proceeding before any court of competent
jurisdiction, the substantially prevailing party shall be entitled to an award of reasonable attorney fee, costs and expenses against
the losing party.

 

[THE
REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 

    	Page 12 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

IN
WITNESS WHEREOF, the parties hereto have properly and duly executed this Agreement as of the date first written above.

 

	THE
    COMPANY: 	 	 	EXECUTIVE:
	VITRO
    DIAGNOSTICS, INC. 	 	 	 
	 	 	 	 	 
	By:	/s/
    James Musick	 	By:	/s/
    Keith Burge
	Printed
    Name: James R. Musick 	 	Printed
    Name: Keith V. Burge
	Title:	CEO
    	 	 	 
	Date:	11/30/20
    	 	Date:	12/2/20
	Address
                                            for Notices: 4621 Technology Drive Golden CO 80403
	 	Address
    for Notices: [***] 

 

    	Page 13 of 15

KVB COO Employment Agreement with Vitro Diagnostics, Inc.

     

    

 

Exhibit
A

 

VITRO
DIAGNOSTICS, INC.

 

NON-STATUTORY
STOCK OPTION AGREEMENT

 

    	 

     

    

 

VITRO
DIAGNOSTICS, INC.

 

NON-STATUTORY
STOCK OPTION AGREEMENT

 

This
Non-Statutory Stock Option Agreement (the “Agreement”) is made and entered into effective the 30th day of November, 2020,
between Vitro Diagnostics, Inc., (the “Company”) and Keith V. Burge (“Optionee”).

 

NOW,
THEREFORE, it is hereby agreed as follows:

 

l. Grant
of Option. The Company hereby grants to Optionee, as of the date hereof, an option to purchase commencing on the date hereof and
ending on the tenth (I0th) anniversary of the date hereof (the “Expiration Date”) an option exercisable to
purchase up to an aggregate of 1.0 million shares of Common Stock, $.001 par value, (the “Option Shares”) at an exercise
price of $0.50 per Option Share (the “Exercise Price”). The Option Shares shall be purchasable from time to time during
the option term specified in this Section I at the Exercise Price, subject to the vesting provisions of paragraph 3 of this
Option.

 

2.
Option Term. This option shall expire at the close of business on the Expiration Date or on the date on which the option shall
have been exercised in full (the “Exercise Date”), unless sooner terminated in accordance with Section 5 hereof

 

3.
Vesting. This Option is subject to the vesting schedule set forth in this paragraph 3. Only Options that have
vested will be exercisable by Optionee. To vest, Optionee must continue to be the chief executive officer to the Company on each
Vesting Date. The number of Options to vest on each Vesting Date is as follows:

 

	Number
    of Options	Vesting
                                            Date

     

	200,000	One
    year anniversary of grant date
	200,000	Two
    year anniversary of grant date
	200,000	Three
    year anniversary of grant date
	200,000	Four
    year anniversary of grant date
	200,000	Fifth
    year anniversary of grant date

 

4.
Limited Transferability.

 

(a)       This
option shall be neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s
death and may be exercised, during Optionee’s lifetime, only by Optionee. However, Optionee may designate one or more persons as
the beneficiary or beneficiaries of this option, and this option shall, in accordance with
such designation, automatically be transferred to such beneficiary or beneficiaries upon the Optionee’s death while holding this
option. Such beneficiary or beneficiaries shall take the transferred option subject to all the terms and conditions of this Agreement,
including (without limitation) the limited time period during which this option may, pursuant to
Section 5, be exercised following Optionee’s death.

 

(b)       If
this option is designated a Non-Statutory Option in the Grant Notice, then this option may be assigned in whole or in part during Optionee’s
lifetime to one or more members of Optionee’s family or to a trust established for the exclusive benefit of one or more such family
members or to Optionee’s former spouse, to the extent such assignment is in connection with the Optionee’s estate plan or
pursuant to a domestic relations order. The assigned portion shall be exercisable only by the person or persons who acquire a proprietary
interest in the option pursuant to such assignment. The terms applicable to the assigned portion shall be the same as those in effect
for this option immediately prior to such assignment.

 

    	 

     

    

 

5.
Cessation of Service. The option term specified in Section 1 survives any cessation of services;
the vested portion of the option shall continue to have the term of exercise as determined by Section I including any transfer
to heirs or beneficiary’s.

 

6.
Adjustment in Option Shares. Should any change be made to the Common Stock
by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares or other change affecting
the outstanding Common Stock as a class without the Company’s receipt of consideration, appropriate adjustments shall be made to
(i) the total number and/or class of securities subject to this option and (ii) the Exercise Price in order to reflect such change and
thereby preclude a dilution or enlargement of benefits hereunder.

 

7.
Stockholder Rights. The holder of this option shall not have any stockholder rights with respect to the Option Shares until such
person shall have exercised the option, paid the Exercise Price and become the record holder of the purchased shares.

 

8.
Manner of Exercising Option.

 

(a)
In order to exercise this option with respect to all
or any part of the Option Shares for which this option is at the time exercisable, Optionee (or any other person or persons exercising
the option) must take the following actions:

 

(i)
Execute and deliver to the Company
a Purchase Agreement for the Option Shares for which
the option is exercised.

 

(ii)
Pay the aggregate Exercise Price for the purchased shares
in one or more of the following forms:

 

(A)
cash or check made payable to the Company; or

 

(B)
a promissory note payable to
the Company, but only to the extent authorized by the
Company.

 

(iii)
Should the Common Stock be registered
under Section 12 of the 1934 Act at the time the option
is exercised, then the Exercise Price may also be paid as follows:

 

(A)
in shares of Common Stock held by Optionee (or any other
person or persons exercising the option) for the requisite period necessary to avoid a charge to the Company’s earnings for financial
reporting purposes and valued at Fair Market Value on the Exercise Date; or

 

(B)
to the extent the option is exercised for Option Shares,
through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall
concurrently provide irrevocable instructions (a) to a Company-designated brokerage firm to effect
the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds available on the settlement date,
sufficient funds to cover the aggregate Exercise Price payable for the purchased shares plus all applicable income and employment taxes
required to be withheld by the Company by reason of such exercise and (b) to the Company to deliver the certificates for the purchased
shares directly to such brokerage firm in order to complete the sale.

 

Except
to the extent the sale and remittance procedure is utilized in connection with the option exercise, payment of the Exercise Price must
accompany the Purchase Agreement delivered to the Company in connection with the option exercise.

 

    	 

     

    

 

(iv)
The exercise price of the Options may also be paid, to the extent permitted by applicable statutes and regulations, either (i) in cash
at the time the Option is exercised, (ii) by delivery to the Company of other Common Stock of the Company valued at its then established
fair market value (as defined below), (iii) by delivery to the Company of either options or stock of the Company including, without limitation,
this Option, valued at the difference between their exercise price and the then established fair market value of the Company’s
Common Stock, (iv) according to a deferred payment or other arrangement (which may include, without limiting the generality of the foregoing,
the use of other Common Stock of the Company) with the holder hereof, or (v) any other form of legal consideration that may be acceptable
to the Board of Directors, in their discretion. For the purposes of this Section 4, the fair market value of the Company’s Common
Stock shall be defined as (i) the closing sale price for the Common Stock on the primary exchange upon which the shares are listed and
traded on the date prior to the date the Option is exercised, or (ii) if the shares are not traded on any national exchange, the closing
sale price for the Common Stock on the NASDAQ National Market on the date prior to the date the Option is exercised, or (iii) if the
shares are neither traded on a national exchange nor listed on the NASDAQ National Market, then the average of the bid and ask prices
for the Common Stock in the Over-The-Counter Market as quoted on the NASDAQ Capital Market, on the date prior to the date the Option
is exercised, or (iv) if the shares of Common Stock are neither traded on a national exchange or the NASDAQ National Market nor quoted
on the NASDAQ Capital Market, the average of the bid and ask prices for the Common Stock as quoted by any recognized securities quotation
service such as the OTC.QB of the OTC Markets Group, LLC or the OTC Electronic Bulletin Board on the date prior to the date the Option
is exercised, or(v) if the shares of Common Stock are not quoted on any recognized securities quotation service such as the OTC.QB of
the OTC Markets Group, LLC or the OTC Electronic Bulletin Board on the date prior to the date the Option is exercised, then the fair
market value of the Company’s Common Stock shall be the price paid for the Company’s Common Stock in the most recent transaction
involving the Company and a nonaffiliated purchaser in an arm’s length transaction {the “Fair Market Value”). In the
case of any deferred payment arrangement, any interest shall be payable at least annually and shall be charged at the minimum rate of
interest necessary to avoid the treatment as interest, under any applicable provisions of the Internal Revenue Code, of any amounts other
than amounts stated to be interest under the deferred payment arrangement.

 

(b)
By way of example, in lieu of exercising this Option by payment with cash, certified check or wired funds, the Holder may elect to receive
the number of Shares, as determined below, equal to the value of this Option (or the portion thereof being exercised) by surrender of
this Option at the corporate office of the Company together with the duly executed form of subscription agreement and notice of such
an election, in which event the Company shall issue to the Holder a number of shares of Common Stock computed using the following formula:

 

X
= Y(A-B)

       A

 

	Where:	 	X
    = the number of shares of Common Stock to be issued to the Holder 
	 	 	Y
    = the gross number of shares of Common Stock to be purchased
	 	 	A=
    the Fair Market Value of one (1) share of the Company’s Common
	 	 	 
	Stock	 	 
	 	 	 
	 	 	       on
    the day prior to exercise hereunder 
	 	 	B=
    Exercise Price

 

(v)
Furnish to the Company appropriate documentation that the person or persons exercising the option ( if other than Optionee) have the
right to exercise this option.

 

    	 

     

    

 

(vi)
Execute and deliver to the Company such written representations as may be requested by the Company in order for it to comply with the
applicable requirements of applicable securities laws.

 

{vii)
Make appropriate arrangements with the Company (or Subsidiary or Affiliate employing or retaining Optionee) for the satisfaction of all
applicable income and employment tax withholding requirements applicable to the option exercise.

 

		(b)	As
                                            soon as practical after the Exercise Date, the Company shall issue to or on behalf of Optionee
                                            (or
                                            any other person or persons exercising this option) a certificate for the purchased Option
                                            Shares, with the appropriate legends affixed thereto.

		(c)	In
                                            no event may this option be exercised for any fractional shares.

 

9.
Compliance with Laws and Regulations.

 

(a)
The exercise of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company and
Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange (or the Nasdaq
National Market, if applicable) on which the Common Stock may be listed for trading at the time of such exercise and issuance.

 

(b)
The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the
lawful issuance and sale of any Common Stock pursuant to this option shall relieve the Company of any 1iability with respect to the non-issuance
or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its best efforts
to obtain all such approvals.

 

 10.
Successors and Assigns. Except to the extent otherwise provided in Sections 3 and 6, the provisions of this Agreement shall insure
to the benefit of, and be binding upon, the Company and its successors and assigns and Optionee, Optionee’s assigns and the legal
representatives, heirs and legatees of Optionee’s estate. 

   

 11.
Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed
to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed
to Optionee at the address indicated below Optionee’s signature line on the Grant Notice. All notices shall be deemed effective
upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified. 

   

 12.
Governing Law. The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of Colorado
without resort to that State’s conflict-of-laws rules. 

 

	Vitro
    Diagnostics, INC 	 	OPTIONEE
	 	 	 	 	 
	By:	/s/
    James Musick	 	By:	/s/
    Keith Burge
	James
    R. Musick, CEO 	 	Keith
    V. BurgeExhibit
10.23

 

ADDENDUM
TO EMPLOYMENT AGREEMENT (PAYMENT PLAN)

 

This ADDENDUM
TO EMPLOMENT AGREEMENT (PAYMENT PLAN) is made and entered into effective this 19th day of February 2021, by and between VITRO
BIOPHARMA, INC., (“Employer” or the “Company”), KEITH BURGE (“Burge” or
“Obligee”), and JACK ZAMORA (“Guarantor”).

 

This
document is in reference to the Employment Agreement dated November 30, 2020 (“Employment Agreement”), between the parties
named above and attached here as Exhibit A. This document is an Addendum to the Employment Agreement and only alters the Employment
Agreement where specifically stated. These additions shall be as valid as if part of the original Employment Agreement. All other provisions
of the Employment Agreement shall remain in full effect subject to the provisions hereof.

 

1.
The Parties agree and hereby stipulate that they are entering into this Agreement to resolve a disputed claim.

 

2.
The Company agrees to make the following payments to Burge (the “Termination Payments”) in full satisfaction of all
obligations of the Company to Burge under the Employment Agreement or arising out of Burge’s employment with the
Company:

 

a. The Company shall pay Burge the sum of $105,000 no later than February 22, 2021.

 

b.
On or before March 1, 2021 and continuing thereafter on or before the first day of each succeeding month thereafter for a total of
eleven consecutive months, the Company shall pay to Burge the sum of $28,636.00 per month, with the last payment due on or before
January 1, 2022.

 

	 	1.	 	Due
    Date: March 1, 2021 / Amount: $28,636.00
	 	ii.	 	Due
    Date: April 1, 2021 / Amount: $28,636.00
		iii.	 	Due Date: May 1, 2021 / Amount: $28,636.00

                                                                                 

		1v.	 	Due Date: June l, 2021 / Amount: $28,636.00
		v.	 	Due Date: July 1, 2021 / Amount: $28,636.00

                                                                                 

		v1.	 	Due Date: August l, 2021 / Amount: $28,636.00
	 	vii.	 	Due
    Date: September 1, 2021 / Amount: $28,636.00
	 	viii.	 	Due Date: October 1, 2021 / Amount: $28,636.00

                                                                      

	 	1x.	 	Due Date: November l, 2021 / Amount: $28,636.00
	 	x.	 	Due
    Date: December 1, 2021 / Amount: $28,636.00
	 	xi.	 	Due
    Date: January 1, 2022 / Amount: $28,636.00

 

    	1

     

    

 

c. All payments owed to Burge pursuant to this agreement shall be paid via direct deposit to:

 

	 	Account Name:Keith & Cindi Burge 	 
	 	Bank: [***] 	 
	 	Account# [***] 	 
	 	ABA # [***] 	 

 

d.
No later than February 22, 2021, the Company shall pay Burge’s legal expenses associated with this matter. Payment shall be made
to [***], in the form of a check, the sum of $10,000.00. The check shall be mailed to:

 

	 	 [***] 	 

 

e.
If any of the above payments are not received within 10 days of the date due after five days’ written notice from Burge, a
late fee of 15% of any outstanding installment shall be automatically imposed. The late fee shall accrue interest at the rate of 15%
per annum until paid.

 

f.
In the event of any dispute associated with this agreement or collection of any late or outstanding payments pursuant to this agreement,
the prevailing party shall be entitled to an award of attorney fees, costs, and expenses against the Company.

 

3.
Jack Zamora personally guarantees the Company’s agreement to make the payments provided for herein. In consideration of the
employment contract between Burge and the Company, the undersigned Guarantor hereby unconditionally guarantees the payment of the
above referenced sums.

 

Burge
understands that Guarantor will be liable to Burge under this Guarantee only after the Company has failed to make a required payment.
A lawsuit may be brought and maintained against the Guarantor by Burge to enforce any liability, obligation or duty guaranteed by this
agreement without the necessity of joining the Company or any other person in the lawsuit.

 

  4. Effective the date above written, Burge hereby resigns his employment by the Company and resigns all positions with the Company, including, without limitation, his position as COO of the Company, such resignations to be effective immediately (the “Termination Date”). From and after the Termination Date, neither party shall represent to the public or to any third party whatsoever that Burge continues to have any association or affiliation with the Company or its affiliates.

 

5.       On
the Termination Date, except for the provisions of the Employment Agreement that survive the termination of Burge’s employment,
all other agreements, arrangements and understandings between the Company and Burge shall terminate and be null and void except as set
forth herein. From and after the Termination Date, Burge shall perform no further services for the Company and the Company shall not
be obligated to Burge in any manner whatsoever.

 

6.
Within five (5) business days of the date of this Agreement, Burge shall return to the Company any and all items of personal property
or equipment belonging to the Company that are in the possession, custody or control of Burge, including, without limitation, any and all documents, memoranda, agreements, contracts, reports and other information in whatsoever form, all hard copy and computer files and computer disks, any and all tools, furniture, computer hardware or software and any other personal property owned by the Company and in the possession, custody or control.

 

    	2

     

    

 

7.
For a period of one year following the Termination Date, Burge agrees that he will not, directly or indirectly as a partner, shareholder,
officer, director, manager or member, engage in any activity that is competitive with the Company; and for a period of two years following
the Termination Date, Burge agrees that he will not, directly or indirectly solicit or attempt to solicit the business of any client
or customer of the Company.

 

8.       Burge
is currently the Optionee under an Option Agreement dated December 9, 2019, attached as Exhibit B, exercisable to purchase up to 3.0
million shares of Company Common Stock at an exercise price of $0.16 per share (“2019 Options”) and another Option Agreement
dated November 30, 2020 exercisable to purchase up to 1.0 million shares of Common Stock at an exercise price of $0.50 per share (“2020
Options”). Both the 2019 Options and 2020 Options are subject to vesting requirements dependent upon continuing service to the
Company. The Company agrees that both the 2019 and 2020 Options shall continue their respective vesting schedules over the next 24 months
following the Termination Date notwithstanding the termination of Burge’s employment. If at the conclusion of the 24 month period
Burge has complied with his obligations under paragraph 7 of this Agreement, , then the Company agrees to waive all remaining vesting
requirements and agrees that all the 2019 and 2020 Options shall be deemed fully vested. In the event Burge violates the provisions of
paragraph 7 of this Agreement, all unvested 2019 or 2020 Options that are outstanding on the date Burge violates paragraph 7 of this
Agreement shall be automatically terminated without notice and no longer exercisable.

 

9.
Burge agrees that as of the Termination Date, and except for the Termination Payments,

 

(a) the Company has no obligation or liability to Burge for compensation, incentive compensation, bonus or other forms of remuneration.

   

(a) The parties stipulate and agree that as of the Termination Date, Burge had no accrued and unpaid hours of unused vacation or wellness leave. The parties agree that no vacation or wellness compensation shall accrue after the Termination Date.

   

(b) Following the Termination Date, the Company shall have no further liability to maintain coverage for Burge under the Company’s health insurance or dental plan; and Burge agrees to look exclusively to Burge’s rights under COBRA for continuing health insurance coverage.

   

(d) Following the Termination Date, the Company shall have no further liability or obligation to Burge to maintain Burge on the Company’s 401K or other pension or retirement plan, deferred compensation plan, auto allowance or to provide Burge with any other perquisite or benefit.

 

    	3

     

     

(e)
Following the Termination Date, Burge shall discontinue use of any and all Company credit cards or other charge or bank accounts on which
he is authorized, it being understood that all such authorizations shall be deemed revoked as of the Termination Date.

 

10.
..In. consideration of the covenants from the Company to Burge set forth herein, Burge, for himself, his executors, administrators, successors
and affiliates, both past and present, hereby irrevocably and unconditionally releases, acquits and forever discharges the Company and
all of its present and former officers, directors, employees, agents, insurers, benefit plans (and related persons/entities), attorneys,
parents, affiliates, subsidiaries, and representatives, (hereafter the “Released Parties”), from any and all charges, complaints,
grievances, actions, suits, liabilities, obligations, promises, agreements, demands, controversies, rights, claims and causes of action
of whatever kind or nature, whether known or unknown, including claims brought under any federal, state or local statute, ordinance or
under common law, including but not limited to, the Civil Rights Act of 1866, the Age Discrimination in Employment Act (“ADEA’’),
the Older Workers’ Benefit Protection Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Family
and Medical Leave Act, the Americans with Disabilities Act, the Burge Retirement Income Security Act, the Colorado Anti-Discrimination
Act and any other employment discrimination or civil rights law, as well as any other claims based on constitutional, statutory, common
law or regulatory grounds, claims for unlawful employment practices arising under any federal, state or local statute, ordinance or regulation;
wrongful discharge; breach of contract; breach of implied contract; failure to keep any promise; breach of covenant of good faith and
fair dealing; breach of fiduciary duties; estoppel; defamation; infliction of emotion distress; fraud; misrepresentation; negligence;
harassment; retaliation or reprisal; constructive discharge; and any all violations of any principal of common law or statute based upon
acts or omissions prior to the date of the execution of this Agreement. Burge also releases all claims for compensation of any kind,
rights to reinstatement, back pay, front pay, compensatory damages, damages for alleged personal injury, liquidated damages, punitive
damages, and all claims for attorneys fees, costs and interest recoverable as a result of claims released by this Agreement, including
claims arising out of tort, contract, or quasi-contract, including claims based upon any of the Accruals, that Burge has or may claim
to have against any of the Released Parties, arising at any time up to and including the date that Burge signs this Agreement.

 

11.
In consideration of the covenants from the Burge to the Company set forth herein, the Company, for itself, its officers, directors, shareholders
and agent, hereby releases, acquits and forever discharges Burge, his agents, representatives, heirs and assigns, from any claim, demand,
obligations or liabilities, known or unknown, at law or in equity, including without limitation, claims arising out of tort, contract
or quasi-contract, and including claims for attorney’s fees, arising from any acts or omissions prior to the execution of this
Agreement. Notwithstanding the generality of the foregoing, Burge shall not be deemed released by virtue of this paragraph IO or any
act or omission committed in the course and scope of his employment which (i) is unknown by the Company and (ii) involves an act of fraud
upon the Company.

 

12.
This Agreement and the rights, obligations, and liabilities under it are to be governed by, and are to be construed and interpreted in
accordance with, the laws of the State of Colorado, Boulder County.

 

13.
The Parties agree that exclusive jurisdiction for any legal action or proceeding arising out of or relating to this Agreement
resides in Boulder County District Court, of the State of Colorado and the Parties further agree and expressly consent to the
exercise of personal jurisdiction

 

In
the State of Colorado in connection with any dispute or claim involving this Agreement.

 

    	4

     

     

14.
This Agreement and the liability and obligations of the Parties hereunder are binding upon the Parties and their heirs, executors, and
assigns, and
inure to the benefit of and are enforceable by t h e P a r t i e s and their successors, transferees, and assigns. None of the terms
or provisions of this Agreement may be waived, altered, modified, or amended, except by an instrument in writing duly executed by the
party to be charged by it. The obligations of the Parties shall remain effective and be enforceable regardless of any subsequent change
in the form of business organization of the Company or any change in the composition, nature, personnel or location of the Company.
The Parties agree that a facsimile copy
of this Agreement shall be considered an original and shall be admissible in a court of law to the same extent as the original document

 

15.
In the event of litigation between or among the signatories hereto to enforce
any provision of this Agreement, the
prevailing party shall be entitled to an award of costs and reasonable attorneys’
fees.

 

IN
WITNESS WHEREOF, the parties to this Agreement have duly executed effective on the day and year first above written.

 

VITRO
BIOPHARMA, INC.

 

	By:	/s/
    Jack Zamora	 	 	Keith
    Burge
	 	Jack
    Zamora  CEO    2/19/21	 	 	/s/
    Keith Burge
	 	Name
    and        Title     Date	 	Date:	2/19/21

 

	Jack
    Zamora 	 
	/s/
    Jack Zamora 	 
	Date
    2/19/21 	 
	 	 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]